middle.news
Immuron’s IMM-529 Gains FDA Nod, Phase 2 Trial Set to Tackle C. diff
3:21pm on Wednesday 5th of November, 2025 AEDT
•
Biotechnology
Read Story
Immuron’s IMM-529 Gains FDA Nod, Phase 2 Trial Set to Tackle C. diff
3:21pm on Wednesday 5th of November, 2025 AEDT
Key Points
FDA approves Immuron’s IND application for IMM-529
Phase 2 clinical trial to commence in Australia in H1 2026
IMM-529 targets prevention and treatment of Clostridioides difficile infection
Trial designed as randomized, double-blind, placebo-controlled with 60 patients
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMC
OPEN ARTICLE